"Epirubicin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA.
| Descriptor ID |
D015251
|
| MeSH Number(s) |
D02.455.426.559.847.562.050.200.175.200 D04.615.562.050.200.175.200 D09.408.051.059.200.175.200
|
| Concept/Terms |
Epirubicin- Epirubicin
- 4'-Epidoxorubicin
- 4' Epidoxorubicin
- 4'-Epi-Doxorubicin
- 4' Epi Doxorubicin
- 4'-Epi-Adriamycin
- 4' Epi Adriamycin
- 4'-Epiadriamycin
- 4' Epiadriamycin
- 4'-Epi-DXR
- 4' Epi DXR
Ellence- Ellence
- Pharmorubicin
- Farmorubicine
- Farmorubicin
|
Below are MeSH descriptors whose meaning is more general than "Epirubicin".
Below are MeSH descriptors whose meaning is more specific than "Epirubicin".
This graph shows the total number of publications written about "Epirubicin" by people in this website by year, and whether "Epirubicin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 3 | 2 | 5 |
| 1995 | 0 | 1 | 1 |
| 1997 | 0 | 1 | 1 |
| 1998 | 0 | 1 | 1 |
| 1999 | 0 | 1 | 1 |
| 2000 | 1 | 1 | 2 |
| 2001 | 0 | 2 | 2 |
| 2002 | 0 | 1 | 1 |
| 2005 | 1 | 2 | 3 |
| 2006 | 0 | 1 | 1 |
| 2007 | 1 | 5 | 6 |
| 2008 | 1 | 3 | 4 |
| 2009 | 0 | 4 | 4 |
| 2010 | 0 | 4 | 4 |
| 2011 | 2 | 1 | 3 |
| 2012 | 0 | 3 | 3 |
| 2013 | 0 | 4 | 4 |
| 2014 | 1 | 1 | 2 |
| 2015 | 1 | 1 | 2 |
| 2016 | 0 | 1 | 1 |
| 2017 | 2 | 3 | 5 |
| 2018 | 0 | 1 | 1 |
| 2019 | 0 | 1 | 1 |
| 2020 | 0 | 1 | 1 |
| 2021 | 0 | 2 | 2 |
| 2023 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Epirubicin" by people in Profiles.
-
Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer (UK TACT2; CRUK/05/19): quality of life results from a multicentre, phase 3, open-label, randomised, controlled trial. Lancet Oncol. 2023 12; 24(12):1359-1374.
-
The Short-Term Efficacy and Safety of Brentuximab Vedotin Plus Cyclophosphamide, Epirubicin and Prednisone in Untreated PTCL: A Real-World, Retrospective Study. Adv Ther. 2022 01; 39(1):532-543.
-
Chemotherapy Versus Chemotherapy Plus Chemoradiation as Neoadjuvant Therapy for Resectable Gastric Adenocarcinoma: A Multi-institutional Analysis. Ann Surg. 2021 10 01; 274(4):544-548.
-
A Randomized Phase II Study of Sequential Eribulin Versus Paclitaxel Followed by FAC/FEC as Neoadjuvant Therapy in Patients with Operable HER2-Negative Breast Cancer. Oncologist. 2021 02; 26(2):e230-e240.
-
Disease-Free and Overall Survival Among Patients With Operable HER2-Positive Breast Cancer Treated With Sequential vs Concurrent Chemotherapy: The ACOSOG Z1041 (Alliance) Randomized Clinical Trial. JAMA Oncol. 2019 01 01; 5(1):45-50.
-
An Organoid-Based Preclinical Model of Human Gastric Cancer. Cell Mol Gastroenterol Hepatol. 2019; 7(1):161-184.
-
Delivery of epirubicin via slow infusion as a strategy to mitigate chemotherapy-induced cardiotoxicity. PLoS One. 2017; 12(11):e0188025.
-
Pharmacogenetic Analysis of the UK MRC (Medical Research Council) MAGIC Trial: Association of Polymorphisms with Toxicity and Survival in Patients Treated with Perioperative Epirubicin, Cisplatin, and 5-fluorouracil (ECF) Chemotherapy. Clin Cancer Res. 2017 Dec 15; 23(24):7543-7549.
-
Randomized trial of Tibetan yoga in patients with breast cancer undergoing chemotherapy. Cancer. 2018 Jan 01; 124(1):36-45.
-
Mismatch Repair Deficiency, Microsatellite Instability, and Survival: An Exploratory Analysis of the Medical Research Council Adjuvant Gastric Infusional Chemotherapy (MAGIC) Trial. JAMA Oncol. 2017 Sep 01; 3(9):1197-1203.